Pipeline

We are building a robust pipeline of transformative medicines addressing inflammatory and autoimmune diseases, and fibrosis.

Using our Deep Biology platform, we are advancing multiple large molecule therapeutic candidates with the potential to be first-in-class therapeutics. Our most advanced product candidates are outlined in the chart below:

Immunology

Program

Target ID & Validation

Lead Optimization

IND Enabling

Phase 1

TRB-051*

IND Enabling

TRB-061

Lead Optimization

TRB-031*

Lead Optimization

TRB-041*

Lead Optimization

TRB-071

Target ID & Validation

TRB-081

Target ID & Validation

*In collaboration with Eli Lilly

Immunology

Oncology

*Partnered with Eli Lilly.

Discovery Pipeline

In addition to these therapeutic programs, we are developing a broad research pipeline by applying our Deep Biology Platform, identifying novel insights into tissue immune-regulation to drive target identification.

Our Collaborations

We have established a number of collaborations and partnerships with leading industry and academic institutions. Notably, we work with Eli Lilly across 3 programs that have been identified and characterized leveraging TRex’s Deep Biology platform : TRB-031, TRB-041, and TRB-051. We also entered into a collaboration with Johnson & Johnson Innovative Medicine for novel targets in Immunology & Inflammation.

Partnered with Lilly